Bio-Rad Laboratories Inc - Class B

Research Bio-Rad Laboratories Inc - Class B (BIO-B) on Bullrun: valuation model: 53.4% overvalued, market cap USD 8.14B, P/E 50.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBIO-B
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryMedical Devices
• CurrencyUSD
• Valuation signal53.4% overvalued
• Market capUSD 8.14B
• P/E50.5
• Financial periodFY2025
• RevenueUSD 2.58B
• Revenue growth0.7%
• Net incomeUSD 759.90M
• Free cash flowUSD 374.60M
• Gross margin51.9%

Valuation Snapshot

Bullrun's latest valuation model marks Bio-Rad Laboratories Inc - Class B as 53.4% overvalued; latest market cap is USD 8.14B; P/E is 50.5.

About Bio-Rad Laboratories Inc - Class B

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.

Frequently asked questions

Is Bio-Rad Laboratories Inc - Class B overvalued or undervalued?

Bullrun's valuation model currently marks Bio-Rad Laboratories Inc - Class B as 53.4% overvalued.

What is Bio-Rad Laboratories Inc - Class B's market cap?

Bio-Rad Laboratories Inc - Class B's market capitalization is USD 8.14B.

What is Bio-Rad Laboratories Inc - Class B's P/E ratio?

Bio-Rad Laboratories Inc - Class B's price-to-earnings (P/E) ratio is 50.5.

What does Bio-Rad Laboratories Inc - Class B do?

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.